Hexb Gene Hexosaminidase Beta is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| infobox |
|---|
| HEXB Gene |
| Full Name |
| Symbol |
| Chromosomal Location |
| NCBI Gene ID |
| OMIM |
| Ensembl ID |
| UniProt |
| Associated Diseases |
The HEXB gene (Hexosaminidase Subunit Beta) is located on chromosome 5q13.3 and encodes the beta subunit of β-hexosaminidase. Together with the alpha subunit (encoded by HEXA), it forms the heterodimeric enzyme Hex A. Mutations in HEXB cause Sandhoff disease, a severe lysosomal storage disorder similar to Tay-Sachs but with additional accumulation of globotriaosylceramide (Gb3). The HEXB gene is also involved in the AB variant of GM2 gangliosidosis.
The HEXB gene encodes the beta subunit of β-hexosaminidase, a lysosomal hydrolase essential for catabolism of GM2 ganglioside and other N-acetylhexosamine-containing compounds.
The beta subunit partners with the alpha subunit (from HEXA) to form hexosaminidase A (Hex A), or pairs with another beta subunit to form hexosaminidase B (Hex B):
| Enzyme | Subunits | Substrate Specificity |
|---|---|---|
| Hex A | α + β | GM2 ganglioside, GAGs, glycoproteins |
| Hex B | β + β | Glycolipids, GAGs (not GM2) |
| Hex S | α + α | Usually inactive |
HEXB produces the beta subunit which:
Sandhoff disease is an autosomal recessive neurodegenerative disorder caused by HEXB mutations resulting in deficient Hex A AND Hex B activity. Unlike Tay-Sachs (HEXA), HEXB deficiency affects both enzymes:
| Feature | Description |
|---|---|
| Onset | Usually within first 6 months |
| Neurodegeneration | Progressive motor/cognitive decline |
| Cherry-red macula | Classic ophthalmologic finding |
| Hepatosplenomegaly | More prominent than Tay-Sachs |
| Fatal outcome | Usually by age 2-4 years |
HEXB is expressed in most tissues:
The beta subunit is essential for proper enzyme assembly and stability. Without it, both Hex A and Hex B are nonfunctional.
| Approach | Strategy | Status |
|---|---|---|
| Gene therapy | AAV-HEXB to CNS | Preclinical |
| Enzyme replacement | Limited by BBB | Experimental |
| Substrate reduction | Reduce ganglioside synthesis | Research |
| Chaperone therapy | Enhance residual activity | Research |
The study of Hexb Gene Hexosaminidase Beta has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Neote K, et al. Structure and function of the HEXB gene encoding the beta-subunit of human beta-hexosaminidase B. Journal of Biological Chemistry. 1988;263(13):6030-6037.
[2] Strømme P, et al. Sandhoff disease: identification of the disease-causing mutation and prenatal diagnosis. Journal of Inherited Metabolic Disease. 1992;15(5):727-734.
[3] Sandhoff K, et al. The GM2 gangliosidoses and their gene defects. Annals of the New York Academy of Sciences. 1998;845:176-185.
[4] Martino S, et al. Enzyme replacement therapy in a mouse model of Sandhoff disease. EMBO Molecular Medicine. 2013;5(7):1068-1082.
[5] Cachón-González MB, et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proceedings of the National Academy of Sciences. 2006;103(27):10373-10378.